State of Cancer Care in America

Since 2014, the American Society of Clinical Oncology (ASCO) has published a series of annual State of Cancer Care in America™ reports to examine important trends in the cancer care delivery system.

Beginning in 2018, ASCO is broadening its State of Cancer Care in America initiative to include national events on pressing cancer care topics, timely in-depth articles that explore certain facets of cancer delivery, and additional materials that detail the current state of cancer care.

View State of Cancer Care reports from prior years.

State of Cancer Care in America Event Series

Watch the recording of ASCO’s inaugural State of Cancer Care in America event: Precision Medicine: Expanding Opportunities.

This month, ASCO will host Precision Medicine: Expanding Opportunities, the inaugural event in ASCO’s new State of Cancer Care in America event series.

Precision Medicine: Expanding Opportunities

January 31, 2018

National Press Club

 

Precision medicine has transformed how cancer is treated and the lens through which it is diagnosed and studied. Yet, the promise of precision medicine can only be fully realized if patients can access resulting discoveries.

Precision Medicine: Expanding Opportunities will focus on the United States’ most urgent challenges in precision medicine – from the overwhelming complexity of tumors, to the costs of treatment, to regulatory barriers that impede widespread use – and the solutions needed to overcome them. 

Event Details

January 31, 2018

12:30 PM – 4:00 PM ET   *Doors open at 12:30 for lunch and networking; first panel begins at 1:00*

Holeman Lounge, National Press Club

529 14th St NW

Washington, DC 

Agenda

Opening Remarks

  • Clifford A. Hudis, MD, FACP, FASCO, Chief Executive Officer, ASCO
  • Bruce E. Johnson, MD, FASCO, President, ASCO
  • Judy Wilkins, Cancer Survivor

Panel 1: Challenges to Realizing the Full Potential of Precision Medicine in Cancer Care

  • Moderator: Richard L. Schilsky, MD, FACP, FASCO, Chief Medical Officer, ASCO

Panelists include:

  • Robert Califf, MD, Vice Chancellor for Health Data Science, Duke Health; Former FDA Commissioner
  • Otis Brawley MD, MACP, FASCO, FACE, Chief Medical Officer, American Cancer Society
  • Suzanne Topalian, MD, Associate Director, Johns Hopkins Bloomberg-Kimmel Institute for Cancer Immunotherapy
  • Anna B. Berry, MD, Scientific Director, Personalized Medicine Program, Swedish Cancer Institute
  • Robert Dubois, MD, PhD, Chief Science Officer and Executive Vice President, National Pharmaceutical Council

Panel 2: Precision Medicine in Practice: Efforts to Accelerate Learning

  • Moderator: Richard L. Schilsky, MD, FACP, FASCO, Chief Medical Officer, ASCO

Panelists include:

  • Barbara L. McAneny, MD, President-Elect, American Medical Association; CEO, New Mexico Oncology Hematology Consultants
  • Edward S. Kim, MD, Chair of Solid Tumor Oncology and Investigational Therapeutics, Levine Cancer Institute; TAPUR Steering Group Chair
  • Meg Gaines, JD, Attorney, Survivor and Founder of the Center for Patient Partnerships, University of Wisconsin
  • Lincoln D. Nadauld, MD, PhD, Medical Director of Cancer Genomics, Intermountain Healthcare